Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박보영 | - |
dc.date.accessioned | 2021-04-06T06:08:48Z | - |
dc.date.available | 2021-04-06T06:08:48Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.citation | CANCERS, v. 12, no. 3, article no. 526 | en_US |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://www.mdpi.com/2072-6694/12/3/526 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/161222 | - |
dc.description.abstract | This study aimed to evaluate the efficacy of anaplastic lymphoma kinase (ALK)-inhibitors in the treatment of ALK-positive non-small cell lung cancer (NSCLC) by using a meta-analysis of clinical trials. We searched PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov by using keywords related to the topic in August 2018. The pooled effect sizes were calculated based on a random-effects model. We also performed subgroup meta-analysis by types of ALK inhibitors (crizotinib, ceritinib, and alectinib). A total of 20 clinical trials with 10 single-arm trials and 10 double-arm trials were included in the final meta-analysis. The median overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), 1 year survival rate, and 2 year survival rate were 19.14 months, 8.47 months, 62%, 78%, 74%, and 62%, respectively. ALK inhibitors showed a significantly superior efficacy compared with chemotherapy (hazard ratio (HR) for OS, 0.83; HR for PFS, 0.43; rate difference (RD) for ORR, 0.23; and RD for DCR, 0.10). The current meta-analysis of clinical trials showed the significant efficacy of ALK inhibitors in the treatment of ALK-positive NSCLC. Further head-to-head trials are needed to compare their efficacy with other types of NSCLC treatment regimens. PROSPERO registration: CRD42018085987. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.subject | ALK inhibitors | en_US |
dc.subject | non-small cell lung cancer | en_US |
dc.subject | crizotinib | en_US |
dc.subject | ceritinib | en_US |
dc.subject | alectinib | en_US |
dc.title | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 12 | - |
dc.identifier.doi | 10.3390/cancers12030526 | - |
dc.relation.page | 526-526 | - |
dc.relation.journal | CANCERS | - |
dc.contributor.googleauthor | Hoang, Tung | - |
dc.contributor.googleauthor | Myung, Seung-Kwon | - |
dc.contributor.googleauthor | Pham, Thu Thi | - |
dc.contributor.googleauthor | Park, Boyoung | - |
dc.relation.code | 2020047041 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | hayejine | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.